$PMCB Pharmacyte Biotech Inc (OTCMKTS:PMCB)’s Technology Attracts International Oncologists (USNA, SBOTD)
Leading biotech company Pharmacyte Biotech Inc (OTCMKTS:PMCB) is known for using high-end technologies to develop drugs for cancer and other diseases. A report says that many international oncologists are getting attracted to the company due to its high-end technology.
Among many world-class oncologists, the famous laboratory and clinical investigator Dr. Manuel Hidalgo has joined the company. Not long ago, he was chosen as one of the Scientific Advisory Board members in the company. Hidalgo is considered as an expert in pancreatic cancer and many other abdominal cancers across the world.
Who Else Is On The Board
Pharmacyte has been actively running its campaign focusing on pancreatic cancer. It’s the latest technologies used by the company that has attracted names like Dr. Daniel Von Hoff of Translational Drug Development in Scottsdale, Arizona and Dr. Matthias Löhr of the Karolinska Institute in Stockholm, Sweden. There are many more names who have appreciated the efforts put by Pharmacyte in one way or another.
If taken into consideration various achievements and research work, one can clearly see that Dr. Manuel Hidalgo is one of the top three experts in pancreatic cancer field in the world. All three of them want to help Pharmacyte in any way possible to ensure that it can develop appropriate treatments and help the patients of pancreatic cancer and other abdominal cancers.
USANA Health Sciences, Inc. (NYSE:USNA) has once again made it to the Utah Business Fast 50 List for the current year. It’s the 8th straight occasion when USANA has managed to find a place among top 50 fastest growing companies in Utah.
Stellar Biotechnologies Inc (OTCMKTS:SBOTD) has decided to execute reverse stock split as part of its preparation for up-listing in NASDAQ Marketplace. Stellar is considered as one of the market leaders in the field of sustainable manufacturing of Keyhole Limpet Hemocyanin. The company is ready to pledge one post-consolidated common share for every ten pre-consolidated shares.
